Core Viewpoint - The Trump administration has advised pregnant women against taking acetaminophen, the active ingredient in Tylenol, due to potential links to autism, while the FDA is updating product labels to reflect this concern [1][2][3] Group 1: FDA and Drug Approval - The FDA is beginning the process of updating the label for Tylenol and similar products to indicate a possible association between acetaminophen use during pregnancy and increased risk of neurological conditions like autism [2] - The FDA has communicated to doctors that while studies suggest an association between acetaminophen and autism, a causal relationship has not been established, and there are conflicting studies in the scientific literature [3] - The FDA is also moving to approve an older GSK drug for treating autism symptoms, which has shown some promise in non-verbal patients, although the studies are small and not widely beneficial [4][5] Group 2: Industry Response and Market Reaction - Ken View has been actively pushing back against claims linking Tylenol to autism, asserting that no scientific evidence supports this connection [7] - The medical community, including organizations like the American College of Obstetrics and Gynecology and the Society for Maternal Fetal Medicine, continues to support the use of acetaminophen during pregnancy, indicating a lack of consensus on the issue [8][9] - Despite the controversy, Ken View shares have seen a rebound, suggesting investor confidence remains strong amid the political discourse surrounding the drug [11]

Company Overview - Can View's stock is rallying approximately 6.5% following the company's pushback against claims linking Tylenol to autism made by the Trump administration [1][2] - The parent company asserts that independent science shows no causal link between acetaminophen and autism, countering the FDA's recent commentary on the potential association [2][3] FDA Commentary - The FDA acknowledged studies suggesting a possible association between acetaminophen use during pregnancy and neurological conditions but emphasized that a causal relationship has not been established [3][6] - Medical professionals have also rejected the claims made regarding Tylenol and autism, supporting the company's position [3][6] Market Impact - Tylenol's stock had previously slumped to its lowest level of the year, but analysts suggest limited judicial risk following the announcement, although public opinion may impact Tylenol consumption [4][5] - Ken View's stock has decreased by approximately 16.5% over the past month, indicating market volatility surrounding the brand [5] Boeing Orders - Boeing's shares increased by 1.5% due to an $8 billion deal with Uzbekistan Airways for 14 Dreamliners, marking the airline's largest order ever [7][9] - This order is expected to support nearly 35,000 jobs in the US and is part of Uzbekistan's plan to expand its international routes [9] AutoZone Performance - AutoZone reported its fifth consecutive earnings miss, with EPS at $48.71, below the expected $50, and revenue just shy of $6.4 billion against a $6.25 billion expectation [10][11] - Despite the misses, AutoZone's stock is up over 20% year-to-date, indicating resilience in the face of tariff impacts and rising costs [11][12] - The company plans to aggressively open new stores in the upcoming year, although it did not provide a 2026 outlook [13]

ToplineShares of Tylenol-maker Kenvue jumped more than 6% as trading opened Tuesday, a day after President Donald Trump linked the use of the drug’s active ingredient during pregnancy to increased risk for autism, despite lacking scientific evidence. Economists saw "limited" risk to the pharmaceutical firm's stock, despite some expected impact on Tylenol consumption.Getty ImagesKey FactsKenvue shares rose about 6.2% to around $18 as trading opened Tuesday, following an earlier rally in premarket while rebou ...

Group 1 - U.S. stock market showed mixed results with Nasdaq down 0.04%, S&P 500 up 0.01%, and Dow Jones up 0.27% [1] - TSMC's stock rose over 3%, reaching a new high, with reports indicating a 20% price increase for the third-generation 3nm process compared to the previous generation, and a projected 50% price increase for the 2nm process to be supplied next year [1] - Boeing's stock increased by over 2% following an $8 billion order from Uzbekistan Airways, with Turkey also planning to purchase hundreds of American aircraft [1] Group 2 - Kenvue, the parent company of Tylenol, saw its stock rise over 7% after the WHO stated there is no consistent evidence linking prenatal exposure to acetaminophen with autism [1]

ToplineShares of Tylenol-maker Kenvue jumped more than 6% in premarket trading on Tuesday, a day after President Donald Trump linked the use of the drug’s active ingredient during pregnancy to increased risk for autism, despite lacking scientific evidence. Economists saw "limited" risk to the pharmaceutical firm's stock, despite some expected impact on Tylenol consumption.Getty ImagesKey FactsKenvue shares rose about 6.7% to around $18.10in early trading Tuesday, rebounding from a 7.4% drop on Monday as the ...

Core Insights - U.S. stock futures showed mixed signals as investors awaited key economic indicators and Federal Reserve Chair Jerome Powell's speech, following a strong session where major indices reached record highs driven by AI optimism and anticipated rate cuts [1][2]. Premarket Trading Activity and Futures Movements - Nasdaq 100 futures rose by 0.04%, while S&P 500 futures were up 0.01% and Dow futures increased by 0.07%, indicating a cautious sentiment among traders ahead of economic data releases [2]. Current Performance of Major Market Indexes - On Monday, the Nasdaq Composite rose 0.70% to close at 22,788.98, the S&P 500 climbed 0.44% to 6,693.75, and the Dow Jones Industrial Average increased by 0.14% to finish at 46,381.54, all achieving new closing highs [4]. Important Upcoming Market Events - Key events include Jerome Powell's speech on monetary policy and the release of flash PMI data, with a focus on the upcoming PCE price index, which is crucial for future policy decisions [5][6]. Major Stock News and Developments - Nvidia's shares surged approximately 4% following a $100 billion deal with OpenAI, while Apple Inc. saw a 4.3% increase due to strong iPhone 17 demand. Oracle Corp. climbed 6.3% after appointing new co-CEOs, and Boeing advanced 2.5% amid U.S.-China aircraft order negotiations [8][10]. - Pfizer announced its acquisition of Metsera for $4.9 billion, causing Metsera's stock to soar over 60%. Other notable movements included Kenvue rebounding 5.7%, Plug Power rising 6.65%, and Firefly Aerospace slumping 11% after financial results [11].

About this content About Ian Lyall Ian Lyall, a seasoned journalist and editor, brings over three decades of experience to his role as Managing Editor at Proactive. Overseeing Proactive's editorial and broadcast operations across six offices on three continents, Ian is responsible for quality control, editorial policy, and content production. He directs the creation of 50,000 pieces of real-time news, feature articles, and filmed interviews annually. Prior to Proactive, Ian helped lead the business outpu ...

Core Viewpoint - Kenvue shares experienced a recovery of over 5% in premarket trading after hitting a record low, following comments made by US President Donald Trump regarding the company's popular pain relief product [1] Group 1 - Kenvue's stock price rose more than 5% in premarket trading on Tuesday [1] - The increase in share price comes after the company reached a record low in the previous session [1] - US President Donald Trump's remarks linked to Kenvue's pain relief product contributed to the recovery in stock price [1]

Group 1 - The core viewpoint is that independent scientific evidence indicates acetaminophen does not cause autism, as stated by a Kenvue spokesperson [1]

Group 1: Technology and AI Investments - Nvidia plans to invest up to $100 billion in Microsoft-backed OpenAI to develop new AI data centers, highlighting its significant role in AI infrastructure [2] - Alibaba has launched its open-source large language model, Qwen3-Omni, which integrates text, image, audio, and video capabilities into a single model [3] Group 2: Aerospace Industry Developments - The U.S. and China are nearing a substantial Boeing aircraft order, potentially involving up to 500 aircraft, which could be Boeing's largest deal with China since 2017 [4] Group 3: Pharmaceutical Industry Concerns - The Trump administration has raised concerns about the use of Tylenol during pregnancy, suggesting a potential link to autism, although this claim lacks scientific backing [5][6] - Kenvue, the maker of Tylenol, maintains that the medication is safe, with estimates indicating it accounts for about 10% of the company's total revenue [7] - The warning regarding Tylenol could lead to increased lawsuits against Kenvue, which has faced around 500 lawsuits since 2022, although previous claims were dismissed due to insufficient evidence [8]